Client News

Home/Client News

First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation

NANTES, France, July 17, 2019 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announces a scientific publication in the American Journal of Transplantation(1). This publication is the first from the Company’s R&D team on SIRPα, a receptor expressed by myeloid lineage cells, and the target of its immuno-oncology program asset BI 765063 (OSE-172).

By | 2019-07-17T16:19:48+00:00 July 17th, 2019|Client News|Comments Off on First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation

Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

ARCHAMPS, France, July 17, 2019 (GLOBE NEWSWIRE) — Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, announced today that the United States Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application allowing the initiation of a Phase 2 trial of the Company`s lead product candidate, […]

By | 2019-07-17T16:18:56+00:00 July 17th, 2019|Client News|Comments Off on Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN

HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) —  Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced that results from a series of studies of the company’s PLX-R18 cell therapy product conducted by the U.S. Department of Defense’s Armed Forces Radiobiology Research […]

By | 2019-07-17T16:16:36+00:00 July 17th, 2019|Client News|Comments Off on Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN

AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease

LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) — AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer™ inhibitor that will be studied in neurodegenerative diseases that are characterized […]

By | 2019-07-17T16:15:46+00:00 July 17th, 2019|Client News|Comments Off on AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease

DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission

CUPERTINO, Calif., July 17, 2019 /PRNewswire/ — DURECT Corporation (DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of DURECT’s full response to the Complete Response Letter (CRL) it previously received from FDA related to POSIMIR®(bupivacaine extended-release solution) is considered by the FDA to be a […]

By | 2019-07-17T16:14:44+00:00 July 17th, 2019|Client News|Comments Off on DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission

CorMedix Presents at FDA Public Meeting on the Limited Population Pathway for Antibacterial and Antifungal Drugs

BERKELEY HEIGHTS, N.J., July 17, 2019 (GLOBE NEWSWIRE) — CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,  announced today that Dr. Phoebe Mounts, Esq., CorMedix Executive Vice President and General Counsel,  presented at a public meeting on July […]

By | 2019-07-17T16:13:45+00:00 July 17th, 2019|Client News|Comments Off on CorMedix Presents at FDA Public Meeting on the Limited Population Pathway for Antibacterial and Antifungal Drugs

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

VANCOUVER, July 17, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NVCN) (NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification (the “Nasdaq […]

By | 2019-07-17T16:12:36+00:00 July 17th, 2019|Client News|Comments Off on Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody

HOLON, Israel, July 16, 2019 /PRNewswire/ — Compugen Ltd.(CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent covering method of use of COM701, a first-in-class therapeutic antibody targeting PVRIG, […]

By | 2019-07-16T17:34:26+00:00 July 16th, 2019|Client News|Comments Off on Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody

Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

SAN DIEGO and TORONTO, July 16, 2019 (GLOBE NEWSWIRE) —  Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that dosing of CG-806, the company’s highly potent, first-in-class pan-FLT3/pan-BTK inhibitor, has commenced its Phase 1a/b dose-escalation study in patients with chronic lymphocytic […]

By | 2019-07-16T16:57:36+00:00 July 16th, 2019|Client News|Comments Off on Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

Vermillion Announces Publication of New Study Demonstrating Overa’s Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone

Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced publication of a paper entitled: “Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays (IVDMIAs) for Presurgical Assessment for Ovarian Cancer Risk” in the journal Advanced Therapeutics (Shulman et al. Adv Ther. July 2019). […]

By | 2019-07-16T16:56:38+00:00 July 16th, 2019|Client News|Comments Off on Vermillion Announces Publication of New Study Demonstrating Overa’s Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone

Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD

CRANBURY, N.J., July 16, 2019 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has dosed the first patient in […]

By | 2019-07-16T16:55:43+00:00 July 16th, 2019|Client News|Comments Off on Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD

MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds

YAVNE, Israel, July 16, 2019 (GLOBE NEWSWIRE) — MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Monday, July 22nd at 12:00pm EDT in New York City.

By | 2019-07-16T16:54:29+00:00 July 16th, 2019|Client News|Comments Off on MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds

Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

VANCOUVER, July 16, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today provided a further update on its Neovasc Reducer™ (the “Reducer”) program […]

By | 2019-07-16T16:53:35+00:00 July 16th, 2019|Client News|Comments Off on Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan

Saint Herblain (France), July 16, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announces today that it has drawn down a further €10 million from  its existing European Investment Bank (EIB) loan facility. The €25 million loan was granted to the […]

By | 2019-07-16T16:52:30+00:00 July 16th, 2019|Client News|Comments Off on Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan

Isofol Announces Recent Advisory Board Meeting Covering Development Plan for Arfolitixorin

GOTHENBURG, Sweden, July 15, 2019 /PRNewswire/ — Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the outcome of an advisory board meeting held to discuss the current status and ongoing strategy for the development of arfolitixorin, the company’s proprietary drug candidate being studied in the global pivotal Phase 3 AGENT […]

By | 2019-07-15T15:47:11+00:00 July 15th, 2019|Client News|Comments Off on Isofol Announces Recent Advisory Board Meeting Covering Development Plan for Arfolitixorin

Orphazyme appoints Kim Stratton as Chief Executive Officer

Copenhagen, July 15, 2019 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company’s Board of Directors has appointed Kim Stratton as the new Chief Executive Officer of Orphazyme, succeeding Anders Hinsby. Kim Stratton will take up her new position on October 1, […]

By | 2019-07-15T15:45:37+00:00 July 15th, 2019|Client News|Comments Off on Orphazyme appoints Kim Stratton as Chief Executive Officer

RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019

TEL-AVIV, Israel and RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment […]

By | 2019-07-15T15:43:20+00:00 July 15th, 2019|Client News|Comments Off on RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019

Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.

GAITHERSBURG, Md., July 15, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc., including the product candidate ALT-801, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH).

By | 2019-07-15T15:42:15+00:00 July 15th, 2019|Client News|Comments Off on Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.

HTG Expands RUO Profiling Menu with New Platform Compatibility Assays

TUCSON, Ariz., July 15, 2019 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the introduction of two of its previously released assays, the HTG EdgeSeqTM DLBCL Cell of Origin Assay and the HTG EdgeSeq Lung Fusions RUO Assay, for […]

By | 2019-07-15T15:40:17+00:00 July 15th, 2019|Client News|Comments Off on HTG Expands RUO Profiling Menu with New Platform Compatibility Assays

Beyond Air™ Announces New NASDAQ Ticker Symbol is XAIR

GARDEN CITY, N.Y. and REHOVOT, Israel, July 15, 2019 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that it has changed its NASDAQ ticker symbol […]

By | 2019-07-15T15:38:42+00:00 July 15th, 2019|Client News|Comments Off on Beyond Air™ Announces New NASDAQ Ticker Symbol is XAIR

NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”

PITTSBURGH, July 15, 2019 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that its common stock began trading on The Nasdaq Capital Market under the ticker symbol “NBSE” at the open of market trading today, July 15, […]

By | 2019-07-15T15:37:35+00:00 July 15th, 2019|Client News|Comments Off on NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”

Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors

HOPKINTON, Mass., July 10, 2019 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Pamela Klein, M.D., has been elected as an independent member of its Board of Directors. Dr. Klein will also serve […]

By | 2019-07-11T12:08:51+00:00 July 11th, 2019|Client News|Comments Off on Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors

iCAD’s ProFound AI™ for 2D Mammography Receives CE Mark Approval

NASHUA, N.H., July 11, 2019 (GLOBE NEWSWIRE) — iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its advanced artificial intelligence technology and workflow solution, ProFound AI™ for 2D Mammography, received CE Mark approval. The technology is the latest addition to iCAD’s deep-learning ProFound AI™ platform, […]

By | 2019-07-11T12:08:09+00:00 July 11th, 2019|Client News|Comments Off on iCAD’s ProFound AI™ for 2D Mammography Receives CE Mark Approval

AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome

LAUSANNE, Switzerland, July 11, 2019 (GLOBE NEWSWIRE) — AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced initial interim data from an ongoing Phase 1b trial of the ACI-24 anti-Abeta vaccine to treat Alzheimer’s disease (AD) like symptoms in subjects with Down syndrome (DS) […]

By | 2019-07-11T12:07:23+00:00 July 11th, 2019|Client News|Comments Off on AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome

Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers

NEW YORK, July 11, 2019 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium”) today highlighted its presence at the Health Physics Society (“HPS”) 64th Annual Meeting that is being held July 7th – 11th in Orlando, Florida. During HPS, Actinium presented the findings of two studies that support the safety […]

By | 2019-07-11T12:06:28+00:00 July 11th, 2019|Client News|Comments Off on Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers

ORYZON to Present Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer’s Association International Conference in Los Angeles

MADRID, Spain and CAMBRIDGE, Mass., July 10, 2019 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will present data from the ongoing Phase IIa clinical trial with vafidemstat in Alzheimer’s disease […]

By | 2019-07-10T12:03:36+00:00 July 10th, 2019|Client News|Comments Off on ORYZON to Present Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer’s Association International Conference in Los Angeles

Orchestra BioMed™ Completes $34 Million Financing to Accelerate Product Pipeline Development and Advance Partnerships

NEW HOPE, Pa., July 10, 2019 (GLOBE NEWSWIRE) —  Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced it has completed a $34 million Series B-1 Preferred Stock financing led by institutional investors Perceptive Advisors, RTW Investments and Soleus Capital […]

By | 2019-07-10T12:01:04+00:00 July 10th, 2019|Client News|Comments Off on Orchestra BioMed™ Completes $34 Million Financing to Accelerate Product Pipeline Development and Advance Partnerships

aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape

SAN DIEGO, July 10, 2019 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a Key Opinion Leader (KOL) call and webcast on pulmonary sarcoidosis and the current treatment landscape on Thursday, […]

By | 2019-07-10T11:59:42+00:00 July 10th, 2019|Client News|Comments Off on aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape